Keňa - angličtina - Pharmacy and Poisons Board

china sinopharm international corporation… 4, huixindongjie, chaoyang district, beijing - virus strain polio virus seed (sabin strain) type… - oral drops - each dose of 2 drops (0.1ml) contains polio virus… - poliomyelitis oral bivalent live attenuated

Keňa - angličtina - Pharmacy and Poisons Board

sanofi pasteur s.a. 2, avenue pont pasteur 69007 lyon france - poliomyelitis virus type 1, ls c2ab strain,… - suspension and effervescent granules for oral - each 0.1-ml dose (2 drops) contains:poliomyelitis… - viral vaccines: poliomyelitis vaccines

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

specialised therapeutics glio pty ltd - aminolevulinic acid hydrochloride, quantity: 1.5 g - oral liquid, powder for - excipient ingredients: - gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant gliomas that are glioblastoma multiforme (gbm) on preoperative imaging, and who are intended for resection of the tumour.

Spojené státy - angličtina - NLM (National Library of Medicine)

daiichi sankyo, inc. - pexidartinib hydrochloride (unii: ys6wai3xn7) (pexidartinib - unii:6783m2lv5x) - turalio is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. none. risk summary based on findings from animal studies and its mechanism of action [see clinical pharmacology (12.1)] , turalio may cause embryo-fetal harm when administered to a pregnant woman. the available human data do not establish the presence or absence of major birth defects or miscarriage related to the use of turalio. oral administration of pexidartinib to pregnant animals during the period of organogenesis resulted in malformations, post-implantation loss, and abortion at maternal exposures that were approximately equal to the human exposure at the recommended dose (see data) . advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 1

Izrael - angličtina - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn or 69 kda omp); pertussis toxoid vaccine; tetanus toxoid - suspension for injection - pertactin (prn or 69 kda omp) 2.5 mcg / 0.5 ml; diphtheria toxoid nlt 2 iu / 0.5 ml; tetanus toxoid nlt 20 iu / 0.5 ml; filamentous haemagglutinin (fha) 8 mcg / 0.5 ml; pertussis toxoid vaccine 8 mcg / 0.5 ml; inactivated polio virus (ipv) type 3 32 du / 0.5 ml; inactivated polio virus (ipv) type 1 40 du / 0.5 ml; inactivated polio virus (ipv) type 2 8 du / 0.5 ml - bacterial and viral vaccines, combined - for booster vaccination against diphtheria, tetanus and pertusis and poliomyelitis of individuals from the age of three years onwards. the administration of boostrix polio should be based on official recommendations.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - polio virus type 1 1e+006 ccid50 (strain lsc 2ab (sabin) not less than 6 log10);  ; polio virus type 2 100000 ccid50 (strain p712 2ab (sabin) not less than 5 log10);  ; polio virus type 3 316227 ccid50 (strain leon 12a 1b (sabin) not less than 5.5 log10);   - oral suspension - 1.4e+006 tcid50 - active: polio virus type 1 1e+006 ccid50 (strain lsc 2ab (sabin) not less than 6 log10)   polio virus type 2 100000 ccid50 (strain p712 2ab (sabin) not less than 5 log10)   polio virus type 3 316227 ccid50 (strain leon 12a 1b (sabin) not less than 5.5 log10)   excipient: arginine magnesium chloride hexahydrate neomycin sulfate polymyxin b sulfate polysorbate 80 purified water

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - polio virus type 1 1e+006 ccid50 (strain lsc, 2ab (sabin), not less than 6 log 10);  ; polio virus type 2 100000 ccid50 (strain p712, 2ab (sabin), ie. not less than 5 log 10);  ; polio virus type 3 630957 ccid50 (strain leon 12a, 1b (sabin), not less than 5.8 log 10);   - oral suspension - active: polio virus type 1 1e+006 ccid50 (strain lsc, 2ab (sabin), not less than 6 log 10)   polio virus type 2 100000 ccid50 (strain p712, 2ab (sabin), ie. not less than 5 log 10)   polio virus type 3 630957 ccid50 (strain leon 12a, 1b (sabin), not less than 5.8 log 10)   excipient: arginine magnesium chloride hexahydrate neomycin sulfate polymyxin b sulfate polysorbate 80 purified water

Tanzanie - angličtina - Tanzania Medicinces & Medical Devices Authority

billion dollars company limited, tanzania - ethanol - solution - 70 %

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg); norethisterone acetate, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; hyprolose; purified talc; magnesium stearate; hypromellose; triacetin - short term symptomatic treatment of postmenopausal oestrogen deficiency (see dosage and administration and clinical trials). for the prevention of postmenopausal bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of kliogest should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing. see precautions and dosage and administration. kliogest is for use in postmenopausal women with an intact uterus. in perimenopausal women treated with kliogest the incidence of vaginal bleeding is unacceptably high and therefore therapy should not be initiated sooner than one year after the last menstrual period.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 1.03 mg (equivalent: estradiol, qty 1 mg); norethisterone acetate, quantity: 0.5 mg - tablet, film coated - excipient ingredients: maize starch; copovidone; lactose monohydrate; purified talc; hypromellose; triacetin; magnesium stearate - short term treatment of menopausal symptoms related to oestrogen deficiency in women more than one year after menopause (see dosage and administration and clinical trials). for the prevention of postmenopausal bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profiles of kliovance should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing. see precautions and dosage and administration.